67-5

78/110

482N, Sato S, Murata A, Tomishima K, Tsuzura H, Sato S, Iijima K, Nagahara A, Genda T: Influence of clostridium butyricum as probi-otics supplementation on helicobacter pylori eradication. Gastroenterology, 2019; 156: S531- S531. 16) Mori H, Suzuki H, Omata F, Masaoka T, Asaoka D, Kawakami K, Mizuno S, Kurihara N, Nagahara A, Sakaki N, Ito M, Kawamura Y, Suzuki M, Shimada Y, Sasaki H, Matsuhisa T, Torii A, Nishizawa T, Mine T, Ohkusa T, Kawai T, Tokunaga K,Takahashi S: Current status of first- and second-line Helicobacter pylori eradication therapy in the metropol-itan area: a multicenter study with a large number of patients. Therap Adv Gastroen-terol. 2019; 12. 17) Tsuzura H, Ikeda Y, Hayashida S, Takahashi S, Amano N, Sato S, Murata A, Sato S, Shimada Y, Iijima K, Genda T: Super para-magnetic iron oxide magnetic resonance imaging (SPIO-MRI) shows impaired phago-cytic function of kupffer cells in severe alco-holic hepatitis. Hepatology. 2019; 70: 850A-851A. 18) Akazawa Y, Hayashi T, Saito T, Niwa K, Kamiyama H, Sasahara N, Sakamoto K, Naga-hara A, Yao T: Histological characteristics of eosinophilic myenteric ganglionitis, an under- recognised cause of chronic intestinal pseu-do-obstruction. Virchows Archiv, 2019; 474: 395-400. 19) Yatagai N, Saito T, Akazawa Y, Hayashi T,Yanai Y, Tsuyama S, Murakami T, Ueyama H,Watanabe S, Nagahara A, Yao T: Frequent loss of heterozygosity of SMAD4 locus and prognostic impacts of SMAD4 immunohisto-chemistry in gastric adenocarcinoma with enteroblastic differentiation. Hum Pathol. 2019 Jun; 88: 18-26. 20) Yatagai N, Saito T,Akazawa Y, Hayashi T, Yanai Y, Tsuyama S, Ueyama H, Murakami T, Watanabe S, Nagahara A, Yao T: TP53 inactivation and expression of methylation- associated proteins in gastric adenocarcinoma with enteroblastic differentiation. Virchows Arch. 2019 Mar; 474: 315-324. 21) Sagawa E, Okubo H, Ando H, Sorin Y, Kanazawa R, Nakadera E, Fukada H, Kokubu S, Miyazaki A: Plasma concentration and effi-cacy of tolvaptan in cirrhotic patients with refractory ascites. J Pharmacol Sci. 2019 Feb 27. 2019; 139: 373-376. 22) Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michi-taka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T: Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. Open Forum Infect Dis. 2019 Apr 15; 6: ofz185. 23) Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H: Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol. 2019 Aug; 54: 742-751. 24) Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Taka-guchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T: Real-world experience of 12-week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection. J Gastro-enterol Hepatol. 2019 Oct 14. doi: 10.1111/jgh.14874. [Epub ahead of print]. 25) Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N,